Effectiveness of COVID-19 vaccine booster doses in adults aged 50 years and over during the Omicron period in Victoria, Australia
DOI:
https://doi.org/10.33321/cdi.2026.50.010Keywords:
SARS-CoV-2, Omicron, relative vaccine effectiveness, Australia, mRNA vaccines, comirnaty, spikevax, hospitalisation, death, pandemic, Cox regression, boosters, waningAbstract
Background
Country-specific estimates of coronavirus disease 2019 (COVID-19) vaccine effectiveness (VE) are important for policy making, but analyses of COVID-19 VE in Australia have been limited to date.
Methods
We used a modified Cox regression model to estimate, through the linkage of national and state-wide health and administrative datasets, the adjusted relative VE of three vs. two and four vs. three COVID-19 vaccine doses against hospitalisation and death due to COVID-19 among Victorians aged ≥ 50 years after the emergence of the Omicron SARS-CoV-2 variant. Analyses were conducted in two periods: 1 December 2021 to 19 June 2022 (Omicron BA.1/2 period; analyses of three vs. two doses); and 20 June 2022 to 7 November 2022 (Omicron BA.4/5 period; analyses of four vs. three doses).
Results
Approximately 1.8 million people were included in analyses of three vs. two doses and approximately 1.2 million people were included in analyses of four vs. three doses. Adjusted relative VE against death 28 days after boosting with a third dose (compared to two doses) in individuals aged ≥ 65 years in the Omicron BA.1/2-dominant period reached 81.2% (95% confidence interval [95% CI]: 76.9–84.6%). There was also evidence for a relative benefit of a third dose in the Omicron BA.1/2 period against hospitalisation (adjusted relative VE 63.6% [95% CI: 60.1–66.8%] 28 days post-boosting) and for a fourth dose in the Omicron BA.4/5 period against hospitalisation and death in this age group. In contrast, estimates of relative VE in the 50–64 year age group were highly imprecise (for example, 52.4% [95% CI: -16.6–80.6%] against death 28 days after receipt of a third dose in the Omicron BA.1/2-dominant period).
Conclusions
These results confirm the benefits of vaccine boosters in the Omicron era for those aged ≥ 65 years, with the most notable gains evident from a third dose in late 2021 to mid-2022.
Downloads
References
Liu B, Gidding H, Stepien S, Cretikos M, Macartney K. Relative effectiveness of COVID-19 vaccination with 3 compared to 2 doses against SARS-CoV-2 B.1.1.529 (Omicron) among an Australian population with low prior rates of SARS-CoV-2 infection. Vaccine. 2022;40(43):6288–94. doi: https://doi.org/10.1016/j.vaccine.2022.09.029.
Smoll NR, Al Imam MH, Schulz C, Booy R, Khandaker G. The effectiveness of vaccination for preventing hospitalisation with COVID-19 in regional Queensland: a data linkage study. Med J Aust. 2023;219(4):162–5. doi: https://doi.org/10.5694/mja2.52019.
Vogt F, Rebuli N, Cretikos M, Liu B, Macartney K, Kaldor J et al. Assessing the effects of SARS-CoV-2 vaccination on the risk of household transmission during delta variant circulation: a population-based data linkage cohort study. Lancet Reg Health West Pac. 2023:42:100930. doi: https://doi.org/10.1016/j.lanwpc.2023.100930.
Liu B, Stepien S, Dobbins T, Gidding H, Henry D, Korda R et al. Effectiveness of COVID-19 vaccination against COVID-19 specific and all-cause mortality in older Australians: a population based study. Lancet Reg Health West Pac. 2023;40:100928. doi: https://doi.org/10.1016/j.lanwpc.2023.100928.
Shearer FM, Edwards L, Kirk M, Eales O, Golding N, Hassall J et al. Opportunities to strengthen respiratory virus surveillance systems in Australia: lessons learned from the COVID-19 response. Commun Dis Intell (2018). 2024;48. doi: https://doi.org/10.33321/cdi.2024.48.47.
Henry DA, Jones MA, Stehlik P, Glasziou PP. Effectiveness of COVID-19 vaccines: findings from real world studies. Med J Aust. 2021;215(4):149–51.e1. doi: https://doi.org/10.5694/mja2.51182.
Australian Bureau of Statistics. National, state and territory population. Reference period: March 2024. [Webpage.] Canberra: Australian Bureau of Statistics; 19 September 2024. [Accessed on 23 October 2024.] Available from: https://www.abs.gov.au/statistics/people/population/national-state-and-territory-population/mar-2024.
Australian COVID-19 Serosurveillance Network. Seroprevalence of SARS-CoV-2-specific antibodies among Australian blood donors: Round 4 update. Sydney: University of New South Wales, Kirby Institute; 8 February 2023. Available from: https://www.kirby.unsw.edu.au/sites/default/files/documents/COVID19-Blood-Donor-Report-Round4-Nov-Dec-2022%5B1%5D.pdf.
Global Initiative on Sharing All Influenza Data (GISAID) via CoVariants.org. SARS-CoV-2 variants in analyzed sequences, Australia. [Website.] Oxford: Global Change Data Lab, Our World in Data; 2024. [Accessed on 18 June 2024.] Available from: https://ourworldindata.org/grapher/covid-variants-area?country=~AUS.
Independent Health and Aged Care Pricing Authority (IHACPA). COVID-19 data in admitted patient care – guidance for data analysts using ICD-10-AM Eleventh Edition, 2022. [Publication.] Sydney: IHACPA; 2022. Available from: https://www.ihacpa.gov.au/sites/default/files/2022-12/How to classify COVID-19 %E2%80%93 Guidance for data analysts using ICD-10-AM Eleventh Edition.PDF.
Lin D, Gu Y, Zeng D, Holloway S. DOVE: Durability of Vaccine Efficacy. [Software.] Vienna: Comprehensive R Archive Network (CRAN); 2022. [Accessed on 22 November 2024.] Available from: https://cran.r-project.org/web/packages/DOVE/index.html.
Lin D-Y, Gu Y, Zeng D, Janes HE, Gilbert PB. Evaluating vaccine efficacy against severe acute respiratory syndrome coronavirus 2 infection. Clin Infect Dis. 2021;74(3):544–52. doi: https://doi.org/10.1093/cid/ciab630.
Lin D-Y, Zeng D, Gilbert PB. Evaluating the long-term efficacy of coronavirus disease 2019 (COVID-19) vaccines. Clin Infect Dis. 2021;73(10):1927–39. doi: https://doi.org/10.1093/cid/ciab226.
Lin DY, Du Y, Xu Y, Paritala S, Donahue M, Maloney P. Durability of XBB.1.5 vaccines against Omicron subvariants. N Engl J Med. 2024;390(22):2124–7. doi: https://doi.org/10.1056/NEJMc2402779.
Australian Bureau of Statistics. Socio-Economic Indexes for Areas. [Internet.] Canberra: Australian Bureau of Statistics; 27 July 2023. [Accessed on 25 September 2024.] Available from: http://www.abs.gov.au/websitedbs/censushome.nsf/home/seifa.
Ikuta KS, Swetschinski LR, Robles Aguilar G, Sharara F, Mestrovic T, Gray AP et al. Global mortality associated with 33 bacterial pathogens in 2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2022;400(10369):2221–48. doi: https://doi.org/10.1016/S0140-6736(22)02185-7.
Canevari JT, Cheng AC, Wu L, Rowe SL, Wollersheim DE, West D et al. The relative effectiveness of three and four doses of COVID-19 vaccine in Victoria, Australia: a data linkage study. Vaccine. 2024;42(1):53–8. doi: https://doi.org/10.1016/j.vaccine.2023.11.047.
Bloomfield LE, Ngeh S, Cadby G, Hutcheon K, Effler PV. SARS-CoV-2 vaccine effectiveness against Omicron variant in infection-naive population, Australia, 2022. Emerg Infect Dis. 2023;29(6):1162–72. doi: https://doi.org/10.3201/eid2906.230130.
Rahman MO, Kamigaki T, Thandar MM, Haruyama R, Yan F, Shibamura-Fujiogi M et al. Protection of the third-dose and fourth-dose mRNA vaccines against SARS-CoV-2 Omicron subvariant: a systematic review and meta-analysis. BMJ Open. 2023;13(12):e076892. doi: https://doi.org/10.1136/bmjopen-2023-076892.
Ackerson BK, Bruxvoort KJ, Qian L, Sy LS, Qiu S, Tubert JE et al. Effectiveness and durability of mRNA-1273 BA.4/BA.5 bivalent vaccine (mRNA-1273.222) against SARS-CoV-2 BA.4/BA.5 and XBB sublineages. Hum Vaccin Immunother. 2024;20(1):2335052. doi: https://doi.org/10.1080/21645515.2024.2335052.
Lin DY, Gu Y, Xu Y, Zeng D, Wheeler B, Young H et al. Effects of vaccination and previous infection on Omicron infections in children. N Eng J Med. 2022;387(12):1141–3. doi: https://doi.org/10.1056/NEJMc2209371.
Bodner K, Irvine MA, Kwong JC, Mishra S. Observed negative vaccine effectiveness could be the canary in the coal mine for biases in observational COVID-19 studies. Int J Infect Dis. 2023;131:111–4. doi: https://doi.org/10.1016/j.ijid.2023.03.022.
Australian Government, Services Australia. AIR vaccine code formats. [Webpage.] Canberra: Service Australia; 2024. [Accessed on 19 June 2024.] Available from: https://www.servicesaustralia.gov.au/air-vaccine-code-formats.
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2026 Communicable Diseases Intelligence
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
